A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

被引：4

作者：

Minh Diem Vu ^{[1
]}

Moser, Samuel ^{[2
]}

Delon, Camille ^{[2
]}

Latzko, Melanie ^{[2
]}

Gianotti, Reto ^{[2
]}

Lueoend, Remo ^{[2
]}

Friang, Chloe ^{[2
]}

Murr, Ramona ^{[2
]}

Duerner, Lydia Jasmin ^{[2
]}

Weinzierl, Tina ^{[2
]}

Fauti, Tanja ^{[2
]}

Bacac, Marina ^{[2
]}

Ast, Oliver ^{[2
]}

Freimoser-Grundschober, Anne ^{[2
]}

Diaz, Tea Rodriguez ^{[2
]}

Zielonka, Joerg ^{[2
]}

van Puijenbroek, Erwin ^{[2
]}

Hosse, Ralf ^{[2
]}

Bruenker, Peter ^{[2
]}

Moessner, Ekkehard ^{[2
]}

Klein, Christian ^{[2
]}

Umana, Pablo ^{[2
]}

Strein, Klaus ^{[1
]}

机构：

[1] EngMab AG, Wilen, Switzerland

[2] Roche Innovat Ctr Zurich, Schlieren, Switzerland

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.2998.2998

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
Tang, Fang
Lu, Yin
Ge, Yongqin
Shang, Jingjing
Zhu, Xiaming
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (01)
[22] Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma
Seckinger, Anja
Delgado, Jose Antonio
Moreno, Laura
Neuber, Brigitte
Grab, Anna
Lipp, Susanne
Merino, Juana
Vu, Minh Diem
Strein, Klaus
Prosper, Felipe
Hundemer, Michael
Miguel, Jesus San
Hose, Dirk
Paiva, Bruno
BLOOD, 2015, 126 (23)
[23] A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma
Sharma, Sheena
Wang, Diane
Lon, Hoi-Kei
Soltantabar, Pooneh
Viqueira, Andrea
Czibere, Akos
Hickman, Anne
White, Jane Liang
Elmeliegy, Mohamed
BLOOD, 2022, 140 : 10036 - 10038
[24] Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
Wang, Ying
Cao, Jiang
Gu, Weiying
Shi, Ming
Lan, Jianping
Yan, Zhiling
Jin, Lai
Xia, Jieyun
Ma, Sha
Liu, Yang
Li, Hujun
Pan, Bin
Chen, Wei
Fei, Xiaoming
Wang, Chunling
Xie, Xiaobao
Yu, Liang
Wang, Gang
Li, Huizhong
Jing, Guangjun
Cheng, Hai
Zhu, Feng
Sun, Haiying
Sang, Wei
Li, Depeng
Li, Zhenyu
Zheng, Junnian
Xu, Kailin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (20) : 2246 - +
[25] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[26] Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
Rodriguez, Cesar
D'Souza, Anita
Shah, Nina
Voorhees, Peter M.
Ben Buelow
Vij, Ravi
Kumar, Shaji K.
BLOOD, 2020, 136
[27] New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)
Moreno, Laura
Zabaleta, Aintzane
Alignani, Diego
Lasa, Marta
Maiso, Patricia
Jelinek, Tomas
Segura, Victor
Delgado, Jose Antonio
Rodriguez-Otero, Paula
Prosper, Felipe
Strein, Klaus
Vu, Minh Diem
Miguel, Jesus San
Paiva, Bruno
BLOOD, 2016, 128 (22)
[28] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Moreau, Philippe
Usmani, Saad Z.
Garfall, Alfred L.
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas
Rosino, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martínez-López, Joaquín
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca I.
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa M.
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita Y.
BLOOD, 2021, 138
[29] A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Sun, Mingyuan
Qi, Junyuan
Qiu, Lugui
Jin, Jie
Li, Xin
Wei, Yongqiang
Zhang, Guimin
Liu, Xue
Yin, Shaohong
BLOOD, 2023, 142
[30] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478

← 1 2 3 4 5 →